LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Science
• Health & Fitness
• Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

patients, ipilimumab, nivolumab, combination, therapy, pubmed, article, trials, checkpoint, google, scholar, melanoma, immunotherapy, cancer, treatment, trial, response, cas, tumor, inhibition, pdl, nct, cell, combined, ctla, mgkg, cells, clinical, monotherapy, phase, checkmate, adverse, events, nsclc, months, pembrolizumab, central, study, immune, weeks, outcomes, advanced, regimens, antictla, pdpdl, data, objective, receiving, survival, regimen,

Topics {✒️}

/press-release/bristolmyers/bristol-myers-squibb-announces-top-line-resultscheckmate-026-phase-3-stu /oncology-times/blog/fdaactionsandupdates/pages/post braf-v600 kinase inhibitor anti-pd-1/pd-l1 moab braf-mutant unresectable/metastatic melanoma pd-1/pd-l1 checkpoint inhibitors anti-ctla-4 immune-checkpoint inhibitor targeting pd-1/pd-l1 interactions anti–pd-1/pd-l1 therapy anti-ctla-4 immune-checkpoint inhibitors anti-tumor t-cell activity pd-1/pd-l1 blockade immunotherapy pan-raf kinase inhibitor /science/article/pii/s1044579x0700034x pd-1/pd-l1 mediated induction anti-lpam-1/α4β7 moab low-dose combination therapy igg4 anti-pd-1 moab anti-pd-l1 moab dual-immune checkpoint inhibition immune-checkpoint inhibitors targeting anticancer monoclonal antibodies pd-1/pd-l1 inhibition pd-l1 mediates peripheral small-cell lung cancer small-cell lung cancer immune-related adverse events anti-pd-1/pd-l1 recurrent squamous-cell carcinoma pd-1/pd-l1 inhibitors igg2 anti-ctla-4 moab programmed death receptor-1 treatment-related adverse events raf kinase inhibitor major histocompatibility complex advancing anti-cancer immunotherapy anti-ctla-4 checkpoint inhibitors single-agent immunotherapy regimens approved monoclonal antibodies tumor pd-l1 status braf protein inhibitor programmed cell death high pd-l1 expression patient-reported outcomes version carboplatin 6 mg/ml/min carboplatin 5 mg/ml/min braf-wild type melanoma tumor pd-l1 expression pd-l1 negative melanoma compare single-agent immunotherapy

Questions {❓}

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
         description:Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
         datePublished:2018-05-16T00:00:00Z
         dateModified:2018-05-16T00:00:00Z
         pageStart:1
         pageEnd:27
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-018-0349-3
         keywords:
            Non-small Cell Lung Cancer (NSCLC)
            Checkpoint Inhibitor Combination
            Single-agent Immunotherapy
            Ipilimumab Combination Therapy
            Recommended Phase 2 Dose (RP2D)
            Oncology
            Immunology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig4_HTML.gif
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Young Kwang Chae
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ayush Arya
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wade Iams
               affiliation:
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marcelo R. Cruz
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sunandana Chandra
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jaehyuk Choi
               affiliation:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francis Giles
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
      description:Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
      datePublished:2018-05-16T00:00:00Z
      dateModified:2018-05-16T00:00:00Z
      pageStart:1
      pageEnd:27
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-018-0349-3
      keywords:
         Non-small Cell Lung Cancer (NSCLC)
         Checkpoint Inhibitor Combination
         Single-agent Immunotherapy
         Ipilimumab Combination Therapy
         Recommended Phase 2 Dose (RP2D)
         Oncology
         Immunology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig4_HTML.gif
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Young Kwang Chae
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ayush Arya
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wade Iams
            affiliation:
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marcelo R. Cruz
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sunandana Chandra
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jaehyuk Choi
            affiliation:
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francis Giles
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:6
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Young Kwang Chae
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ayush Arya
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Wade Iams
      affiliation:
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Marcelo R. Cruz
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Sunandana Chandra
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Jaehyuk Choi
      affiliation:
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Francis Giles
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA

External Links {🔗}(254)

• What's https://www.springernature.com/gp/authors's gross income?
• How much revenue does https://link.springernature.com/home/ produce monthly?
• How much does https://order.springer.com/public/cart bring in each month?
• How much revenue does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research bring in?
• What's the financial outcome of http://clinicaltrials.gov?
• How much revenue does https://doi.org/10.1517%2F14712598.8.8.1151 generate?
• What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18613766?
• How much does http://scholar.google.com/scholar_lookup?&title=Approved%20monoclonal%20antibodies%20for%20cancer%20therapy&journal=Expert%20Opin%20Biol%20Ther&doi=10.1517%2F14712598.8.8.1151&volume=8&issue=8&pages=1151-1158&publication_year=2008&author=Boyiadzis%2CM&author=Foon%2CKA gross monthly?
• How much profit is https://doi.org/10.1038%2Fnrc3236 making per month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22437872 rake in every month?
• How profitable is http://scholar.google.com/scholar_lookup?&title=Antibody%20therapy%20of%20cancer&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc3236&volume=12&issue=4&pages=278-287&publication_year=2012&author=Scott%2CAM&author=Wolchok%2CJD&author=Old%2CLJ?
• How much revenue does https://doi.org/10.1111%2Fj.1476-5381.2009.00190.x bring in?
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19459844?
• How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697811 generate?
• Find out how much http://scholar.google.com/scholar_lookup?&title=Therapeutic%20antibodies%3A%20successes%2C%20limitations%20and%20hopes%20for%20the%20future&journal=Br%20J%20Pharmacol&doi=10.1111%2Fj.1476-5381.2009.00190.x&volume=157&issue=2&pages=220-233&publication_year=2009&author=Chames%2CP&author=Van%20Regenmortel%2CM&author=Weiss%2CE&author=Baty%2CD earns monthly
• How much income is https://doi.org/10.4161/mabs.1.3.8292 earning monthly?
• How much profit is https://doi.org/10.1016%2Fj.nbt.2011.03.021 making per month?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Antibodies%20in%20oncology&journal=New%20Biotechnol&doi=10.1016%2Fj.nbt.2011.03.021&volume=28&issue=5&pages=518-529&publication_year=2011&author=Pillay%2CV&author=Gan%2CHK&author=Scott%2CAM
• How much does https://doi.org/10.1073%2Fpnas.0915174107 rake in every month?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20160101 make?
• How much income does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840093 have?
• How much profit does http://scholar.google.com/scholar_lookup?&title=PD-1%20and%20CTLA-4%20combination%20blockade%20expands%20infiltrating%20T%20cells%20and%20reduces%20regulatory%20T%20and%20myeloid%20cells%20within%20B16%20melanoma%20tumors&journal=Proc%20Natl%20Acad%20Sci&doi=10.1073%2Fpnas.0915174107&volume=107&issue=9&pages=4275-4280&publication_year=2010&author=Curran%2CMA&author=Montalvo%2CW&author=Yagita%2CH&author=Allison%2CJP make?
• How much does https://doi.org/10.1172%2FJCI80011 earn?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26325035 makes per month
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588282 pull in monthly?
• How much income does http://scholar.google.com/scholar_lookup?&title=Anti%E2%80%93PD-1%2FPD-L1%20therapy%20of%20human%20cancer%3A%20past%2C%20present%2C%20and%20future&journal=J%20Clin%20Invest&doi=10.1172%2FJCI80011&volume=125&issue=9&pages=3384-3391&publication_year=2015&author=Chen%2CL&author=Han%2CX have?
• How much does https://journals.lww.com/oncology-times/blog/fdaactionsandupdates/pages/post.aspx?PostID=116 make?
• Get to know https://www.cancer.gov/publications/dictionaries's earnings
• Get to know what's the income of https://doi.org/10.1097%2FCOC.0000000000000239
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26558876 make?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892769 pull in?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=CTLA-4%20and%20PD-1%20pathways%3A%20similarities%2C%20differences%2C%20and%20implications%20of%20their%20inhibition&journal=Am%20J%20Clin%20Oncol&doi=10.1097%2FCOC.0000000000000239&volume=39&issue=1&pages=98-106&publication_year=2016&author=Buchbinder%2CEI&author=Desai%2CA bring in?
• Get to know what's the income of https://doi.org/10.1016%2FS1074-7613%2802%2900362-X
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12196291?
• Income figures for http://scholar.google.com/scholar_lookup?&title=The%20interaction%20properties%20of%20costimulatory%20molecules%20revisited&journal=Immunity&doi=10.1016%2FS1074-7613%2802%2900362-X&volume=17&issue=2&pages=201-210&publication_year=2002&author=Collins%2CAV&author=Brodie%2CDW&author=Gilbert%2CRJ&author=Iaboni%2CA&author=Manso-Sancho%2CR&author=Walse%2CB&author=Stuart%2CDI&author=van%20der%20Merwe%2CPA&author=Davis%2CSJ
• How much does https://doi.org/10.1146%2Fannurev.immunol.19.1.565 rake in every month?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11244047 generate?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=CTLA-4-mediated%20inhibition%20in%20regulation%20of%20T%20cell%20responses%3A%20mechanisms%20and%20manipulation%20in%20tumor%20immunotherapy&journal=Annu%20Rev%20Immunol&doi=10.1146%2Fannurev.immunol.19.1.565&volume=19&issue=1&pages=565-594&publication_year=2001&author=Chambers%2CCA&author=Kuhns%2CMS&author=Egen%2CJG&author=Allison%2CJP bring in?
• How much revenue does https://doi.org/10.1146%2Fannurev.immunol.26.021607.090331 generate?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18173375's total income per month
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=PD-1%20and%20its%20ligands%20in%20tolerance%20and%20immunity&journal=Annu%20Rev%20Immunol&doi=10.1146%2Fannurev.immunol.26.021607.090331&volume=26&pages=677-704&publication_year=2008&author=Keir%2CME&author=Butte%2CMJ&author=Freeman%2CGJ&author=Sharpe%2CAH?
• Discover the revenue of https://doi.org/10.1038%2Fni0702-611
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12087419 earning monthly?
• http://scholar.google.com/scholar_lookup?&title=CTLA-4%3A%20new%20insights%20into%20its%20biological%20function%20and%20use%20in%20tumor%20immunotherapy&journal=Nat%20Immunol&doi=10.1038%2Fni0702-611&volume=3&issue=7&pages=611-618&publication_year=2002&author=Egen%2CJG&author=Kuhns%2CMS&author=Allison%2CJP's financial summary
• What's the revenue for https://doi.org/10.1128%2FMCB.25.21.9543-9553.2005?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16227604?
• What's the income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1265804?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=CTLA-4%20and%20PD-1%20receptors%20inhibit%20T-cell%20activation%20by%20distinct%20mechanisms&journal=Mol%20Cell%20Biol&doi=10.1128%2FMCB.25.21.9543-9553.2005&volume=25&issue=21&pages=9543-9553&publication_year=2005&author=Parry%2CRV&author=Chemnitz%2CJM&author=Frauwirth%2CKA&author=Lanfranco%2CAR&author=Braunstein%2CI&author=Kobayashi%2CSV&author=Linsley%2CPS&author=Thompson%2CCB&author=Riley%2CJL?
• How much income is https://doi.org/10.4049%2Fjimmunol.164.10.5319 earning monthly?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10799894
• http://scholar.google.com/scholar_lookup?&title=Structural%20analysis%20of%20CTLA-4%20function%20in%20vivo&journal=J%20Immunol&doi=10.4049%2Fjimmunol.164.10.5319&volume=164&issue=10&pages=5319-5327&publication_year=2000&author=Masteller%2CEL&author=Chuang%2CE&author=Mullen%2CAC&author=Reiner%2CSL&author=Thompson%2CCB's total income per month
• How much profit does https://doi.org/10.1084%2Fjem.182.2.459 make?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7543139
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=CD28%20and%20CTLA-4%20have%20opposing%20effects%20on%20the%20response%20of%20T%20cells%20to%20stimulation&journal=J%20Exp%20Med&doi=10.1084%2Fjem.182.2.459&volume=182&issue=2&pages=459-465&publication_year=1995&author=Krummel%2CMF&author=Allison%2CJP?
• How much money does https://doi.org/10.1016%2FS1074-7613%2800%2980480-X make?
• What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8673700?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Intracellular%20trafficking%20of%20CTLA-4%20and%20focal%20localization%20towards%20sites%20of%20TCR%20engagement&journal=Immunity&doi=10.1016%2FS1074-7613%2800%2980480-X&volume=4&issue=6&pages=535-543&publication_year=1996&author=Linsley%2CPS&author=Bradshaw%2CJ&author=Greene%2CJ&author=Peach%2CR&author=Bennett%2CKL&author=Mittler%2CRS?
• Get to know https://doi.org/10.1084%2Fjem.192.2.303's earnings
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10899917?
• See how much http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193248 makes per month
• Income figures for http://scholar.google.com/scholar_lookup?&title=Immunologic%20self-tolerance%20maintained%20by%20CD25%2B%20CD4%2B%20regulatory%20T%20cells%20constitutively%20expressing%20cytotoxic%20T%20lymphocyte%E2%80%93associated%20antigen%204&journal=J%20Exp%20Med&doi=10.1084%2Fjem.192.2.303&volume=192&issue=2&pages=303-310&publication_year=2000&author=Takahashi%2CT&author=Tagami%2CT&author=Yamazaki%2CS&author=Uede%2CT&author=Shimizu%2CJ&author=Sakaguchi%2CN&author=Mak%2CTW&author=Sakaguchi%2CS
• Get to know https://doi.org/10.1002%2Fj.1460-2075.1992.tb05481.x's earnings
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1396582 produce monthly?
• Explore the financials of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC556898
• How much profit does http://scholar.google.com/scholar_lookup?&title=Induced%20expression%20of%20PD-1%2C%20a%20novel%20member%20of%20the%20immunoglobulin%20gene%20superfamily%2C%20upon%20programmed%20cell%20death&journal=EMBO%20J&doi=10.1002%2Fj.1460-2075.1992.tb05481.x&volume=11&issue=11&publication_year=1992&author=Ishida%2CY&author=Agata%2CY&author=Shibahara%2CK&author=Honjo%2CT make?
• How much does https://doi.org/10.1038%2Fnri1349 pull in monthly?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15122199
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Co-inhibitory%20molecules%20of%20the%20B7%E2%80%93CD28%20family%20in%20the%20control%20of%20T-cell%20immunity&journal=Nat%20Rev%20Immunol&doi=10.1038%2Fnri1349&volume=4&issue=5&pages=336-347&publication_year=2004&author=Chen%2CL
• Profit of https://doi.org/10.1158%2F1078-0432.CCR-13-3271
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24714771?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185001 bring in each month?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Association%20of%20PD-1%2C%20PD-1%20ligands%2C%20and%20other%20features%20of%20the%20tumor%20immune%20microenvironment%20with%20response%20to%20anti%E2%80%93PD-1%20therapy&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-13-3271&volume=20&issue=19&pages=5064-5074&publication_year=2014&author=Taube%2CJM&author=Klein%2CA&author=Brahmer%2CJR&author=Xu%2CH&author=Pan%2CX&author=Kim%2CJH&author=Chen%2CL&author=Pardoll%2CDM&author=Topalian%2CSL&author=Anders%2CRA generate?
• How much does https://doi.org/10.1084%2Fjem.20051776 net monthly?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16606670?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118286 income
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Tissue%20expression%20of%20PD-L1%20mediates%20peripheral%20T%20cell%20tolerance&journal=J%20Exp%20Med&doi=10.1084%2Fjem.20051776&volume=203&issue=4&pages=883-895&publication_year=2006&author=Keir%2CME&author=Liang%2CSC&author=Guleria%2CI&author=Latchman%2CYE&author=Qipo%2CA&author=Albacker%2CLA&author=Koulmanda%2CM&author=Freeman%2CGJ&author=Sayegh%2CMH&author=Sharpe%2CAH?
• What's the income of https://doi.org/10.1084%2Fjem.193.7.839?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11283156?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193370
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=B7-DC%2C%20a%20new%20dendritic%20cell%20molecule%20with%20potent%20costimulatory%20properties%20for%20T%20cells&journal=J%20Exp%20Med&doi=10.1084%2Fjem.193.7.839&volume=193&issue=7&pages=839-846&publication_year=2001&author=Tseng%2CS-Y&author=Otsuji%2CM&author=Gorski%2CK&author=Huang%2CX&author=Slansky%2CJE&author=Pai%2CSI&author=Shalabi%2CA&author=Shin%2CT&author=Pardoll%2CDM&author=Tsuchiya%2CH
• How much does https://doi.org/10.4161%2Fonci.21335 bring in each month?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Targeting%20PD-1%2FPD-L1%20interactions%20for%20cancer%20immunotherapy&journal=Oncoimmunol&doi=10.4161%2Fonci.21335&volume=1&issue=8&pages=1223-1225&publication_year=2012&author=Zitvogel%2CL&author=Kroemer%2CG
• What's the income generated by https://doi.org/10.1038%2Fnm730 each month?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12091876
• Get to know http://scholar.google.com/scholar_lookup?&title=Tumor-associated%20B7-H1%20promotes%20T-cell%20apoptosis%3A%20a%20potential%20mechanism%20of%20immune%20evasion&journal=Nat%20Med&doi=10.1038%2Fnm730&volume=8&issue=8&pages=793-800&publication_year=2002&author=Dong%2CH&author=Strome%2CSE&author=Salomao%2CDR&author=Tamura%2CH&author=Hirano%2CF&author=Flies%2CDB&author=Roche%2CPC&author=Lu%2CJ&author=Zhu%2CG&author=Tamada%2CK's earnings
• Explore the financials of https://doi.org/10.1073%2Fpnas.192461099
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12218188's gross income?
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC129438 produce monthly?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Involvement%20of%20PD-L1%20on%20tumor%20cells%20in%20the%20escape%20from%20host%20immune%20system%20and%20tumor%20immunotherapy%20by%20PD-L1%20blockade&journal=Proc%20Natl%20Acad%20Sci&doi=10.1073%2Fpnas.192461099&volume=99&issue=19&pages=12293-12297&publication_year=2002&author=Iwai%2CY&author=Ishida%2CM&author=Tanaka%2CY&author=Okazaki%2CT&author=Honjo%2CT&author=Minato%2CN?
• Income figures for https://doi.org/10.1182%2Fblood-2006-11-060087
• How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17289811 making per month?
• What's the income generated by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1896111 each month?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Interaction%20between%20B7-H1%20and%20PD-1%20determines%20initiation%20and%20reversal%20of%20T-cell%20anergy&journal=Blood&doi=10.1182%2Fblood-2006-11-060087&volume=110&issue=1&pages=180-185&publication_year=2007&author=Tsushima%2CF&author=Yao%2CS&author=Shin%2CT&author=Flies%2CA&author=Flies%2CS&author=Xu%2CH&author=Tamada%2CK&author=Pardoll%2CDM&author=Chen%2CL
• Learn how profitable https://doi.org/10.1158%2F0008-5472.CAN-12-4100 is on a monthly basis
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23633484
• Earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686913
• How much does http://scholar.google.com/scholar_lookup?&title=Dual%20blockade%20of%20PD-1%20and%20CTLA-4%20combined%20with%20tumor%20vaccine%20effectively%20restores%20T-cell%20rejection%20function%20in%20tumors&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-12-4100&volume=73&issue=12&pages=3591-3603&publication_year=2013&author=Duraiswamy%2CJ&author=Kaluza%2CKM&author=Freeman%2CGJ&author=Coukos%2CG net monthly?
• How much revenue does https://www.sciencedirect.com/science/article/pii/S1044579X0700034X bring in?
• What's the financial outcome of https://doi.org/10.1038%2Fni1102-991?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12407406
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%3A%20from%20immunosurveillance%20to%20tumor%20escape&journal=Nat%20Immunol&doi=10.1038%2Fni1102-991&volume=3&issue=11&pages=991-998&publication_year=2002&author=Dunn%2CGP&author=Bruce%2CAT&author=Ikeda%2CH&author=Old%2CLJ&author=Schreiber%2CRD
• How much does https://doi.org/10.1172%2FJCI22685 net monthly?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15314682
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC503781
• Find out how much http://scholar.google.com/scholar_lookup?&title=Immune%20recognition%20of%20self%20in%20immunity%20against%20cancer&journal=J%20Clin%20Invest&doi=10.1172%2FJCI22685&volume=114&issue=4&pages=468-471&publication_year=2004&author=Houghton%2CAN&author=Guevara-Pati%C3%B1o%2CJA earns monthly
• How much income is https://doi.org/10.1126%2Fscience.1203486 earning monthly?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21436444?
• http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%3A%20integrating%20immunity%E2%80%99s%20roles%20in%20cancer%20suppression%20and%20promotion&journal=Science&doi=10.1126%2Fscience.1203486&volume=331&issue=6024&pages=1565-1570&publication_year=2011&author=Schreiber%2CRD&author=Old%2CLJ&author=Smyth%2CMJ income
• What are the earnings of https://doi.org/10.1111%2Fj.1365-2567.2007.02587.x?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17386080 pull in?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265921 pull in monthly?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%20from%20immune%20surveillance%20to%20immune%20escape&journal=Immunology&doi=10.1111%2Fj.1365-2567.2007.02587.x&volume=121&issue=1&pages=1-14&publication_year=2007&author=Kim%2CR&author=Emi%2CM&author=Tanabe%2CK?
• What's the total monthly financial gain of https://doi.org/10.1158%2F1078-0432.CCR-14-1860?
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25501578's gross income?
• How much does http://scholar.google.com/scholar_lookup?&title=Immune%20escape%20mechanisms%20as%20a%20guide%20for%20cancer%20immunotherapy&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-1860&volume=21&issue=4&pages=687-692&publication_year=2015&author=Beatty%2CGL&author=Gladney%2CWL make?
• Profit of https://doi.org/10.1093%2Fannonc%2Fmds262
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22918927 have?
• How much does http://scholar.google.com/scholar_lookup?&title=Combination%20immunotherapy%20approaches&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmds262&volume=23&issue=suppl%208&pages=viii41-viii46&publication_year=2012&author=Drake%2CC bring in each month?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21626032
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Camouflage%20and%20sabotage%3A%20tumor%20escape%20from%20the%20immune%20system&journal=Cancer%20Immunol%20Immunother&doi=10.1007%2Fs00262-011-1012-8&volume=60&issue=8&pages=1161-1171&publication_year=2011&author=Poschke%2CI&author=Mougiakakos%2CD&author=Kiessling%2CR
• Profit of https://doi.org/10.1172%2FJCI31405
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17476343 make?
• How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857231 make?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Immune%20surveillance%20of%20tumors&journal=J%20Clin%20Invest&doi=10.1172%2FJCI31405&volume=117&issue=5&pages=1137-1146&publication_year=2007&author=Swann%2CJB&author=Smyth%2CMJ
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Classification%20of%20current%20anticancer%20immunotherapies&journal=Oncotarget&volume=5&pages=12472-12508&publication_year=2015&author=Galluzzi%2CL&author=Vacchelli%2CE&author=Pedro%2CB-S&author=Buqu%C3%A9%2CA&author=Senovilla%2CL&author=Baracco%2CEE&author=Bloy%2CN&author=Castoldi%2CF&author=Abastado%2CJ-P&author=Agostinis%2CP
• How much revenue does https://doi.org/10.1056%2FNEJMoa1602252 generate?
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=Nivolumab%20for%20recurrent%20squamous-cell%20carcinoma%20of%20the%20head%20and%20neck&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1602252&volume=2016&issue=375&pages=1856-1867&publication_year=2016&author=Ferris%2CRL&author=Blumenschein%2CG&author=Fayette%2CJ&author=Guigay%2CJ&author=Colevas%2CAD&author=Licitra%2CL&author=Harrington%2CK&author=Kasper%2CS&author=Vokes%2CEE&author=Even%2CC each month?
• How much revenue does https://doi.org/10.1200%2FJCO.2014.59.0703 generate?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25452452's total income per month
• How much does http://scholar.google.com/scholar_lookup?&title=Nivolumab%20for%20metastatic%20renal%20cell%20carcinoma%3A%20results%20of%20a%20randomized%20phase%20II%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2014.59.0703&volume=33&issue=13&pages=1430-1437&publication_year=2015&author=Motzer%2CRJ&author=Rini%2CBI&author=McDermott%2CDF&author=Redman%2CBG&author=Kuzel%2CTM&author=Harrison%2CMR&author=Vaishampayan%2CUN&author=Drabkin%2CHA&author=George%2CS&author=Logan%2CTF pull in?
• What are the total earnings of https://doi.org/10.1056%2FNEJMoa1507643?
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26412456?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936 income
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20nonsquamous%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1507643&volume=373&issue=17&pages=1627-1639&publication_year=2015&author=Borghaei%2CH&author=Paz-Ares%2CL&author=Horn%2CL&author=Spigel%2CDR&author=Steins%2CM&author=Ready%2CNE&author=Chow%2CLQ&author=Vokes%2CEE&author=Felip%2CE&author=Holgado%2CE each month?
• How much revenue does https://doi.org/10.1056%2FNEJMoa1504627 produce monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26028407 pull in?
• Financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20squamous-cell%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504627&volume=373&issue=2&pages=123-135&publication_year=2015&author=Brahmer%2CJ&author=Reckamp%2CKL&author=Baas%2CP&author=Crin%C3%B2%2CL&author=Eberhardt%2CWE&author=Poddubskaya%2CE&author=Antonia%2CS&author=Pluzanski%2CA&author=Vokes%2CEE&author=Holgado%2CE?
• How much revenue does https://doi.org/10.1016%2FS1470-2045%2815%2970076-8 generate?
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25795410?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20chemotherapy%20in%20patients%20with%20advanced%20melanoma%20who%20progressed%20after%20anti-CTLA-4%20treatment%20%28CheckMate%20037%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20phase%203%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2815%2970076-8&volume=16&issue=4&pages=375-384&publication_year=2015&author=Weber%2CJS&author=D%27Angelo%2CSP&author=Minor%2CD&author=Hodi%2CFS&author=Gutzmer%2CR&author=Neyns%2CB&author=Hoeller%2CC&author=Khushalani%2CNI&author=Miller%2CWH&author=Lao%2CCD?
• https://doi.org/10.1056%2FNEJMoa1411087 income
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25482239 net monthly?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=PD-1%20blockade%20with%20nivolumab%20in%20relapsed%20or%20refractory%20Hodgkin%27s%20lymphoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1411087&volume=372&issue=4&pages=311-319&publication_year=2015&author=Ansell%2CSM&author=Lesokhin%2CAM&author=Borrello%2CI&author=Halwani%2CA&author=Scott%2CEC&author=Gutierrez%2CM&author=Schuster%2CSJ&author=Millenson%2CMM&author=Cattry%2CD&author=Freeman%2CGJ
• How much revenue does https://doi.org/10.1056%2FNEJMoa1501824 bring in?
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25891174 earning monthly?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20for%20the%20treatment%20of%20non%E2%80%93small-cell%20lung%20Cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1501824&volume=372&issue=21&pages=2018-2028&publication_year=2015&author=Garon%2CEB&author=Rizvi%2CNA&author=Hui%2CR&author=Leighl%2CN&author=Balmanoukian%2CAS&author=Eder%2CJP&author=Patnaik%2CA&author=Aggarwal%2CC&author=Gubens%2CM&author=Horn%2CL?
• How much does https://doi.org/10.1056%2FNEJMoa1503093 rake in every month?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25891173 generate?
• http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20versus%20Ipilimumab%20in%20Advanced%20Melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1503093&volume=372&issue=26&pages=2521-2532&publication_year=2015&author=Robert%2CC&author=Schachter%2CJ&author=Long%2CGV&author=Arance%2CA&author=Grob%2CJJ&author=Mortier%2CL&author=Daud%2CA&author=Carlino%2CMS&author=McNeil%2CC&author=Lotem%2CM income
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Antitumor%20activity%20and%20safety%20of%20pembrolizumab%20in%20patients%20%28pts%29%20with%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28SCCHN%29%3A%20preliminary%20results%20from%20KEYNOTE-012%20expansion%20cohort&publication_year=2015&author=Seiwert%2CTY&author=Haddad%2CRI&author=Gupta%2CS&author=Mehra%2CR&author=Tahara%2CM&author=Berger%2CR&author=Lee%2CS-H&author=Burtness%2CB&author=Le%2CDT&author=Heath%2CK?
• How much cash flow does https://doi.org/10.1016%2FS0140-6736%2816%2900561-4 have monthly?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26952546?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242?
• How much does http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900561-4&volume=387&issue=10031&pages=1909-1920&publication_year=2016&author=Rosenberg%2CJE&author=Hoffman-Censits%2CJ&author=Powles%2CT&author=van%20der%20Heijden%2CMS&author=Balar%2CAV&author=Necchi%2CA&author=Dawson%2CN&author=O%27Donnell%2CPH&author=Balmanoukian%2CA&author=Loriot%2CY make?
• What's the monthly money flow for https://doi.org/10.1016%2FS0140-6736%2816%2900587-0?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26970723?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20%28POPLAR%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%202%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900587-0&volume=387&issue=10030&pages=1837-1846&publication_year=2016&author=Fehrenbacher%2CL&author=Spira%2CA&author=Ballinger%2CM&author=Kowanetz%2CM&author=Vansteenkiste%2CJ&author=Mazieres%2CJ&author=Park%2CK&author=Smith%2CD&author=Artal-Cortes%2CA&author=Lewanski%2CC?
• https://doi.org/10.1056%2FNEJMoa1302369's revenue stream
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23724867's earnings
• What is the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698004?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Nivolumab%20plus%20ipilimumab%20in%20advanced%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1302369&volume=369&issue=2&pages=122-133&publication_year=2013&author=Wolchok%2CJD&author=Kluger%2CH&author=Callahan%2CMK&author=Postow%2CMA&author=Rizvi%2CNA&author=Lesokhin%2CAM&author=Segal%2CNH&author=Ariyan%2CCE&author=Gordon%2CR-A&author=Reed%2CK?
• How much does https://doi.org/10.1056%2FNEJMoa1504030 pull in monthly?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Combined%20nivolumab%20and%20ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504030&volume=2015&issue=373&pages=23-34&publication_year=2015&author=Larkin%2CJ&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Grob%2CJJ&author=Cowey%2CCL&author=Lao%2CCD&author=Schadendorf%2CD&author=Dummer%2CR&author=Smylie%2CM&author=Rutkowski%2CP?
• How much money does https://doi.org/10.1056%2FNEJMoa1709684 make?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28889792?
• What are the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1709684&volume=377&issue=14&pages=1345-1356&publication_year=2017&author=Wolchok%2CJD&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Rutkowski%2CP&author=Grob%2CJ-J&author=Cowey%2CCL&author=Lao%2CCD&author=Wagstaff%2CJ&author=Schadendorf%2CD&author=Ferrucci%2CPF?
• https://doi.org/10.1016%2FS1470-2045%2816%2930126-7's revenue stream
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27269740 generate?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305?
• How much does http://scholar.google.com/scholar_lookup?&title=Sequential%20administration%20of%20nivolumab%20and%20ipilimumab%20with%20a%20planned%20switch%20in%20patients%20with%20advanced%20melanoma%20%28CheckMate%20064%29%3A%20an%20open-label%2C%20randomised%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2930126-7&volume=17&issue=7&pages=943-955&publication_year=2016&author=Weber%2CJS&author=Gibney%2CG&author=Sullivan%2CRJ&author=Sosman%2CJA&author=Slingluff%20Jr%2CCL&author=Lawrence%2CDP&author=Logan%2CTF&author=Schuchter%2CLM&author=Nair%2CS&author=Fecher%2CL generate monthly?
• What are the total earnings of https://doi.org/10.1016%2FS1470-2045%2817%2930428-X?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28729151
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Standard-dose%20pembrolizumab%20in%20combination%20with%20reduced-dose%20ipilimumab%20for%20patients%20with%20advanced%20melanoma%20%28KEYNOTE-029%29%3A%20an%20open-label%2C%20phase%201b%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2817%2930428-X&volume=18&issue=9&pages=1202-1210&publication_year=2017&author=Long%2CGV&author=Atkinson%2CV&author=Cebon%2CJS&author=Jameson%2CMB&author=Fitzharris%2CBM&author=McNeil%2CCM&author=Hill%2CAG&author=Ribas%2CA&author=Atkins%2CMB&author=Thompson%2CJA bring in?
• https://doi.org/10.1200%2FJCO.2016.34.15_suppl.3001's total income per month
• Earnings of http://scholar.google.com/scholar_lookup?&title=CheckMate%20012%3A%20safety%20and%20efficacy%20of%20first-line%20%281L%29%20nivolumab%20%28nivo%3B%20N%29%20and%20ipilimumab%20%28ipi%3B%20I%29%20in%20advanced%20%28adv%29%20NSCLC&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2016.34.15_suppl.3001&volume=34&issue=Suppl&publication_year=2016&author=Hellmann%2CM&author=Gettinger%2CS&author=Goldman%2CJ&author=Brahmer%2CJ&author=Borghaei%2CH&author=Chow%2CL&author=Ready%2CN&author=Gerber%2CD&author=Juergens%2CR&author=Shepherd%2CF
• What's the financial gain of https://doi.org/10.1016%2FS1470-2045%2815%2900544-6?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26858122 earns monthly
• What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500167?
• How much does http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumour%20activity%20of%20durvalumab%20plus%20tremelimumab%20in%20non-small%20cell%20lung%20cancer%3A%20a%20multicentre%2C%20phase%201b%20study&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2815%2900544-6&volume=17&issue=3&pages=299-308&publication_year=2016&author=Antonia%2CS&author=Goldberg%2CSB&author=Balmanoukian%2CA&author=Chaft%2CJE&author=Sanborn%2CRE&author=Gupta%2CA&author=Narwal%2CR&author=Steele%2CK&author=Gu%2CY&author=Karakunnel%2CJJ pull in monthly?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26380628 make?
• Revenue of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570074
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Combination%20immunotherapy%20superior%20to%20monotherapy%20in%20patients%20with%20melanoma&journal=Am%20Health%20Drug%20Benefits&volume=8&issue=Spec%20Issue&publication_year=2015&author=Doyle%2CC
• What's the total monthly financial gain of https://doi.org/10.1056%2FNEJMoa1200690?
• What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22658127?
• Revenue of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544539
• How much does http://scholar.google.com/scholar_lookup?&title=Safety%2C%20activity%2C%20and%20immune%20correlates%20of%20anti%E2%80%93PD-1%20antibody%20in%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1200690&volume=366&issue=26&pages=2443-2454&publication_year=2012&author=Topalian%2CSL&author=Hodi%2CFS&author=Brahmer%2CJR&author=Gettinger%2CSN&author=Smith%2CDC&author=McDermott%2CDF&author=Powderly%2CJD&author=Carvajal%2CRD&author=Sosman%2CJA&author=Atkins%2CMB earn?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26027431
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905 have monthly?
• How much income is http://scholar.google.com/scholar_lookup?&title=Combined%20Nivolumab%20and%20Ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504030&volume=373&issue=1&pages=23-34&publication_year=2015&author=Larkin%2CJ&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Grob%2CJJ&author=Cowey%2CCL&author=Lao%2CCD&author=Schadendorf%2CD&author=Dummer%2CR&author=Smylie%2CM&author=Rutkowski%2CP earning monthly?
• How much does https://doi.org/10.1200%2FJCO.2017.73.2289 pull in?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28841387?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791828 bring in each month?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20outcomes%20in%20patients%20with%20advanced%20melanoma%20who%20discontinued%20treatment%20with%20nivolumab%20and%20ipilimumab%20because%20of%20adverse%20events%3A%20a%20pooled%20analysis%20of%20randomized%20phase%20II%20and%20III%20trials&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2017.73.2289&volume=35&issue=34&pages=3807-3814&publication_year=2017&author=Schadendorf%2CD&author=Wolchok%2CJD&author=Hodi%2CFS&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Rutkowski%2CP&author=Grob%2CJ-J&author=Cowey%2CCL&author=Lao%2CCD&author=Chesney%2CJ?
• Get to know what's the income of https://doi.org/10.1016%2FS1470-2045%2816%2930098-5
• How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27269741 making per month?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Nivolumab%20alone%20and%20nivolumab%20plus%20ipilimumab%20in%20recurrent%20small-cell%20lung%20cancer%20%28CheckMate%20032%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201%2F2%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2930098-5&volume=17&issue=7&pages=883-895&publication_year=2016&author=Antonia%2CSJ&author=L%C3%B3pez-Martin%2CJA&author=Bendell%2CJ&author=Ott%2CPA&author=Taylor%2CM&author=Eder%2CJP&author=J%C3%A4ger%2CD&author=Pietanza%2CMC&author=Le%2CDT&author=de%20Braud%2CF generate?
• What's the monthly income of https://doi.org/10.1093%2Fjnci%2Fdju244?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25265940 bring in each month?
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200059 have monthly?
• What's http://scholar.google.com/scholar_lookup?&title=Development%20of%20the%20National%20Cancer%20Institute%E2%80%99s%20patient-reported%20outcomes%20version%20of%20the%20common%20terminology%20criteria%20for%20adverse%20events%20%28PRO-CTCAE%29&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdju244&volume=106&issue=9&publication_year=2014&author=Basch%2CE&author=Reeve%2CBB&author=Mitchell%2CSA&author=Clauser%2CSB&author=Minasian%2CLM&author=Dueck%2CAC&author=Mendoza%2CTR&author=Hay%2CJ&author=Atkinson%2CTM&author=Abernethy%2CAP's gross income?
• What's the income generated by https://doi.org/10.1056%2FNEJMoa1606774 each month?
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27718847?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20versus%20chemotherapy%20for%20PD-L1%E2%80%93positive%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1606774&volume=375&issue=19&pages=1823-1833&publication_year=2016&author=Reck%2CM&author=Rodr%C3%ADguez-Abreu%2CD&author=Robinson%2CAG&author=Hui%2CR&author=Cs%C5%91szi%2CT&author=F%C3%BCl%C3%B6p%2CA&author=Gottfried%2CM&author=Peled%2CN&author=Tafreshi%2CA&author=Cuffe%2CS
• https://news.bms.com/press-release/bristolmyers/bristol-myers-squibb-announces-top-line-resultscheckmate-026-phase-3-stu's financial summary
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=NSCLC%2C%20metastaticCheckMate%20026%3A%20a%20phase%203%20trial%20of%20nivolumab%20vs%20investigator%27s%20choice%20%28IC%29%20of%20platinum-based%20doublet%20chemotherapy%20%28PT-DC%29%20as%20first-line%20therapy%20for%20stage%20iv%2Frecurrent%20programmed%20death%20ligand%201%20%28PD-L1%29%E2%88%92%20positive%20NSCLC&journal=Ann%20Oncol&volume=27&issue=suppl%206&publication_year=2016&author=Socinski%2CM&author=Creelan%2CB&author=Horn%2CL&author=Reck%2CM&author=Paz-Ares%2CL&author=Steins%2CM&author=Felip%2CE&author=van%20den%20Heuvel%2CM&author=Ciuleanu%2CT&author=Badin%2CF?
• How much money does https://doi.org/10.1016%2FS1470-2045%2816%2900175-3 generate?
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27157491 have monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20for%20patients%20with%20PD-L1-positive%20advanced%20gastric%20cancer%20%28KEYNOTE-012%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201b%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2900175-3&volume=17&issue=6&pages=717-726&publication_year=2016&author=Muro%2CK&author=Chung%2CHC&author=Shankaran%2CV&author=Geva%2CR&author=Catenacci%2CD&author=Gupta%2CS&author=Eder%2CJP&author=Golan%2CT&author=Le%2CDT&author=Burtness%2CB produce monthly?
• Find out how much https://doi.org/10.1371%2Fjournal.pone.0189848 earns monthly
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29284010?
• Monthly income for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746232
• Income figures for http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumor%20activity%20of%20the%20anti%E2%80%93PD-1%20antibody%20pembrolizumab%20in%20patients%20with%20advanced%20colorectal%20carcinoma&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0189848&volume=12&issue=12&publication_year=2017&author=O%E2%80%99Neil%2CBH&author=Wallmark%2CJM&author=Lorente%2CD&author=Elez%2CE&author=Raimbourg%2CJ&author=Gomez-Roca%2CC&author=Ejadi%2CS&author=Piha-Paul%2CSA&author=Stein%2CMN&author=Razak%2CARA
• How much money does https://doi.org/10.1016%2Fj.ejca.2017.01.009 generate?
• Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28214657
• How much profit does http://scholar.google.com/scholar_lookup?&title=Ipilimumab%20alone%20or%20in%20combination%20with%20nivolumab%20after%20progression%20on%20anti-PD-1%20therapy%20in%20advanced%20melanoma&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2017.01.009&volume=75&pages=47-55&publication_year=2017&author=Zimmer%2CL&author=Apuri%2CS&author=Eroglu%2CZ&author=Kottschade%2CLA&author=Forschner%2CA&author=Gutzmer%2CR&author=Schlaak%2CM&author=Heinzerling%2CL&author=Krackhardt%2CAM&author=Loquai%2CC generate?
• Income figures for https://doi.org/10.1002%2Fcpt.88
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Innovative%20clinical%20trials%3A%20the%20LUNG-MAP%20study&journal=Clin%20Pharmacol%20Therapeutics&doi=10.1002%2Fcpt.88&volume=97&issue=5&pages=488-491&publication_year=2015&author=Steuer%2CC&author=Papadimitrakopoulou%2CV&author=Herbst%2CR&author=Redman%2CM&author=Hirsch%2CF&author=Mack%2CP&author=Ramalingam%2CS&author=Gandara%2CD?
• Profit of https://citation-needed.springer.com/v2/references/10.1186/s40425-018-0349-3?format=refman&flavour=references
• How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Young%20Kwang%20Chae making per month?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Young%20Kwang%20Chae%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ayush%20Arya?
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ayush%20Arya%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wade%20Iams's financial summary
• What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wade%20Iams%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
• How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marcelo%20R.%20Cruz?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marcelo%20R.%20Cruz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sunandana%20Chandra make?
• What are the total earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sunandana%20Chandra%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jaehyuk%20Choi
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jaehyuk%20Choi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
• Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Francis%20Giles
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Francis%20Giles%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What's the financial outcome of http://creativecommons.org/licenses/by/4.0/?
• How much does http://creativecommons.org/publicdomain/zero/1.0/ net monthly?
• What's the income of https://s100.copyright.com/AppDispatchServlet?title=Current%20landscape%20and%20future%20of%20dual%20anti-CTLA4%20and%20PD-1%2FPD-L1%20blockade%20immunotherapy%20in%20cancer%3B%20lessons%20learned%20from%20clinical%20trials%20with%20melanoma%20and%20non-small%20cell%20lung%20cancer%20%28NSCLC%29&author=Young%20Kwang%20Chae%20et%20al&contentID=10.1186%2Fs40425-018-0349-3©right=The%20Author%28s%29.&publication=2051-1426&publicationDate=2018-05-16&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY%20%2B%20CC0?
• How much does https://crossmark.crossref.org/dialog/?doi=10.1186/s40425-018-0349-3 pull in?
• How much profit does https://citation-needed.springer.com/v2/references/10.1186/s40425-018-0349-3?format=refman&flavour=citation make?
• Revenue of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral
• How much does https://www.springernature.com/gp/products earn?
• What's the total monthly financial gain of https://www.springernature.com/gp/librarians?
• Discover the revenue of https://www.springernature.com/gp/societies
• Financial intake of https://www.springernature.com/gp/partners
• Income figures for https://www.springer.com/
• What are the total earnings of https://www.nature.com/?
• How much does https://www.biomedcentral.com/ gross monthly?
• How much does https://www.palgrave.com/ make?
• How much does https://www.apress.com/ pull in?
• What's the financial outcome of https://www.springernature.com/gp/legal/ccpa?
• How much revenue does https://www.springernature.com/gp/info/accessibility generate?
• What's the total monthly financial gain of https://support.springernature.com/en/support/home?
• https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations's revenue stream
• How much does https://www.springernature.com/ pull in?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Pace
• Prism.js

CDN Services {📦}

• Crossref